NCT07678177 An Observational Study to Evaluate the Efficacy and Safety of K-CAB Tab./K-CAB ODT(Tegoprazan) in GERD Patients
| NCT ID | NCT07678177 |
| Status | Recruiting |
| Phase | — |
| Sponsor | HK inno.N Corporation |
| Condition | GERD (Gastroesophageal Reflux Disease) |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,384 participants |
| Start Date | 2023-03-07 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,384 participants in total. It began in 2023-03-07 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the status of AE and improvement effect of K-CAB Tab/K-CAB ODT(Tegoprazan) 50mg in patients with GERD.
Eligibility Criteria
Inclusion Criteria: 1. Subjects over 19 years of age as of the date of consent 2. Subjects with a total score of 8 or more in the Korean Gastroesophageal Reflux Disease Questionnaire (GerdQ) based on Visit 1 3. Subjects who voluntarily decides to participate and agrees in writing to the consent form of the study Exclusion Criteria: 1. Subjects who have hypersensitivity reactions and a medical history of Benzimidazole or components of the investigational drug 2. Subjects on Atazanavir, Nelfinavir, or Rilpivirine-containing medications 3. Pregnant and lactating women
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07678177 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying GERD (Gastroesophageal Reflux Disease). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07678177 currently recruiting?
Yes, NCT07678177 is actively recruiting participants. Contact the research team at yongan.jeong@inno-n.com for enrollment information.
Where is the NCT07678177 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07678177 clinical trial?
NCT07678177 is sponsored by HK inno.N Corporation. The trial plans to enroll 5,384 participants.